Form 4: DENTSPLY SIRONA Director Janet Vergis Reports RSU Dividend Acquisition

DENTSPLY SIRONA Inc. Director Janet S. Vergis reported the acquisition of 139.41 additional restricted stock units (RSUs) as dividends, increasing her total beneficial ownership to 44,120.718 RSUs.

Summary

• Janet S. Vergis, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 139.41 shares of Common Stock on July 11, 2025.
• This acquisition represents dividends on previously awarded restricted stock units (RSUs).
• The newly acquired RSUs are subject to the same vesting terms as the underlying awards and vest simultaneously.
• Each RSU converts to common stock on a 1:1 basis.
• Following this transaction, Ms. Vergis beneficially owns 44,120.718 shares of Common Stock (in the form of RSUs).
• The transaction price was $0, consistent with a dividend distribution.

Sentiment

Score: 7

Explanation: The transaction is a routine, non-cash acquisition of dividend equivalents on RSUs by a director, which is a positive for aligning interests but not a significant market-moving event. It reflects standard compensation practices.

Positives

• Increase in director's beneficial ownership, albeit through non-cash dividends, aligns director's interests with shareholders.
• The acquisition of RSUs as dividends indicates the company's RSU program includes dividend equivalents, which can enhance long-term retention and alignment.

Negatives

• No direct cash investment by the director in this specific transaction.

Future Outlook

N/A. This document is a Form 4 filing reporting a past transaction and does not contain forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the acquisition of dividend equivalents on restricted stock units by a director. Such transactions are common in the compensation structures of publicly traded companies across various industries, including the dental products and technologies sector where DENTSPLY SIRONA operates. It reflects standard corporate governance practices regarding executive and director compensation.

Comparison to Industry Standards

• The practice of granting restricted stock units (RSUs) as part of director compensation, and including dividend equivalents on those RSUs, is a common and widely accepted practice across industries, including healthcare and medical device sectors.
• Companies like Align Technology (ALGN) or Henry Schein (HSIC), which operate in related or adjacent markets, often utilize similar equity-based compensation structures to align director and executive interests with long-term shareholder value.
• The $0 transaction price for dividend-related RSU acquisitions is standard, as these are not purchases but rather accruals based on existing equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of additional restricted stock units by a director, even as dividends, aligns the director's long-term interests with shareholder value creation, as the value of these units is tied to the company's stock performance.

Next Steps

• The acquired restricted stock units (RSUs) will vest according to the terms of the underlying awards, converting to common stock on a 1:1 basis upon vesting.

Key Dates

Recommendation

Keywords

DENTSPLY SIRONA, XRAY, Janet S. Vergis, Form 4, SEC filing, insider transaction, restricted stock units, RSU, dividend, beneficial ownership, corporate governance, director compensation